a Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 17, 2023, at 2:00 pm CET following the announcement of results for the second quarter and first half of 2023.
Press Release – No. 9 / 2023
Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results
Copenhagen, Denmark, August 14, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 17, 2023, at 2:00 pm CET (8:00 am ET) following the announcement of results for the second quarter and first half of 2023.
Presenting during the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The presentation will be followed by a Q&A session. The conference call will be conducted in English.
Telephone dial-in information and a unique personal access PIN will be provided upon registration at https://register.vevent.com/register/BI08d950a0d12f438da57a04a02449f692.
A live audio webcast of the conference call and accompanying slide presentation will be available at https://edge.media-server.com/mmc/p/5hqhqe4i and accessible through the company’s website at www.zealandpharma.com/events-cal where a recording of the webcast will also be archived after the event.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
Contacts:
| Adam Lange (Investors) |
| Investor Relations Officer |
| Zealand Pharma |
| akl@zealandpharma.com |
| Anna Krassowska, PhD (Investors and Media) |
| Vice President, Investor Relations & Corporate Communications |
| Zealand Pharma |
| ank@zealandpharma.com |
